Department of Paediatric Cardiology and Congenital Heart Disease, Deutsches Herzzentrum München (DHM), Technische Universität München (TUM), Germany.
Department of Paediatric Cardiology and Congenital Heart Disease, Deutsches Herzzentrum München (DHM), Technische Universität München (TUM), Germany; Department of Paediatrics, Faculty of Medicine, Zagazig University, Egypt.
Int J Cardiol. 2021 May 15;331:82-87. doi: 10.1016/j.ijcard.2021.01.038. Epub 2021 Feb 3.
In our study, we sought to analyse the mid-term results after interventional aortic coarctation (CoA) stenting with sequential dilation of the stent.
The data of all 218 patients, who are above the age of 6 years and underwent CoA-stent implantation in our hospital, were retrospectively analysed on the rate of re-interventions, complications and arterial hypertension at a follow-up time of 31 months. To avoid any aortic complications, stents were deployed primarily not in full size and a second cardiac catheterisation for further dilatation was scheduled within 6-12 months after the stent implantation.
The median peak invasive systolic pressure gradient declined significantly from 26.2 mmHg to 2.7 mmHg after stenting. There was one procedure related death due to an aortic rupture after stent implantation. There were in total 33 (15.1%) procedure-related complications including femoral artery complications, stent fracture and stent dislocation (in 9, 9 and 7 patients, respectively). In 85 patients a re-dilatation and in 25 patients a second stent-implantation was necessary at the first re-intervention. The systolic blood pressure declined significantly from 144 mmHg to 131 mmHg after stenting. The number of patients being normotensive changed from 18% before stenting to 78.5% after stenting with adjusted antihypertensive medication.
Aortic stenting is an effective means for CoA treatment. With sequential dilation of the stent, a very low rate of life-threatening procedural complications and mortality can be achieved. CoA stenting with proper antihypertensive medications results in better control of blood pressure.
在我们的研究中,我们试图分析经皮腔内主动脉缩窄(CoA)支架置入术后支架序贯扩张的中期结果。
回顾性分析了 218 例年龄大于 6 岁且在我院行 CoA 支架置入术患者的资料,随访 31 个月时,分析再介入率、并发症和动脉高血压的发生率。为避免任何主动脉并发症,支架最初不扩张至全尺寸,并在支架置入后 6-12 个月内进行第二次心脏导管插入术以进一步扩张。
支架置入后,峰值侵入性收缩压梯度中位数从 26.2mmHg 显著下降至 2.7mmHg。支架置入后发生 1 例主动脉破裂相关的手术相关死亡。共有 33 例(15.1%)与手术相关的并发症,包括股动脉并发症、支架断裂和支架脱位(分别为 9、9 和 7 例患者)。85 例患者在首次再介入时需要再次扩张,25 例患者需要再次支架植入。支架置入后收缩压从 144mmHg 显著下降至 131mmHg。支架置入前,需要调整降压药物的高血压患者比例为 18%,支架置入后,该比例增加至 78.5%。
主动脉支架置入术是治疗 CoA 的有效方法。通过支架序贯扩张,可以实现非常低的危及生命的手术并发症和死亡率。适当的降压药物治疗 CoA 支架置入术后可更好地控制血压。